DBS Method Validation
Posted on Fri, Jun 24, 2011 @ 09:58 AM
The challenges and solutions for the bioanalysis industry were top of the agenda at our exclusive bioanalysis seminar last week in Munich, Germany.
The seminar was attended by representatives from pharmaceutical and biotechnology organisations across Europe and featured debates and panel discussions from leading industry speakers on new techniques and hot topics including the latest industry guidelines.
Regulatory considerations for DBS analysis
Richard Houghton, Principal Scientist for Bioanalytical Sciences at Quotient, opened the seminar with a discussion on the validation of DBS methods for use in regulated bioanalysis. He highlighted the advantages and disadvantages of DBS and talked about the relevant regulatory considerations addressing several specific issues including blood spot volume and haematocrit assessment.
The seminar also featured a senior level speaker from a leading Pharmaceutical company who is actively involved in the European Bioanalytical Forum (EBF) and led a very interesting discussion of new and emerging guidelines on principles of method validation. Other contributors included Sigma-Aldrich, looking at mobile phase considerations for analysis of peptides and proteins with LC-MS and Waters, focusing on the application of an integrated microfluidic device for the high sensitivity analysis of pharmaceutical and endogenous compounds in biological fluids.
This is the first seminar we have hosted in mainland Europe and from the response we are already plans for another. Our next seminar will be held at the Fordham, Cambridgeshire, UK site on the 5th October 2011, further details will be available on the website soon.
Download full press release